Stock Traders Purchase High Volume of Forte Biosciences Put Options (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRX) saw some unusual options trading activity on Monday. Traders bought 2,105 put options on the company. This is an increase of approximately 2,116% compared to the typical volume of 95 put options.

Institutional Trading of Forte Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of FBRX. Candriam S.C.A. acquired a new stake in shares of Forte Biosciences in the 1st quarter worth about $2,196,000. 683 Capital Management LLC bought a new stake in shares of Forte Biosciences in the 4th quarter worth approximately $1,091,000. Royal Bank of Canada lifted its position in shares of Forte Biosciences by 6.5% during the 4th quarter. Royal Bank of Canada now owns 11,986 shares of the company’s stock valued at $327,000 after acquiring an additional 733 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Forte Biosciences in the fourth quarter worth about $302,000. Finally, Alps Advisors Inc. acquired a new stake in shares of Forte Biosciences in the fourth quarter worth $281,000. 77.63% of the stock is owned by institutional investors and hedge funds.

Forte Biosciences Price Performance

FBRX traded up $21.66 during trading on Monday, reaching $76.44. 10,436,877 shares of the stock were exchanged, compared to its average volume of 434,091. Forte Biosciences has a 1 year low of $9.10 and a 1 year high of $76.48. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -16.48 and a beta of 2.85. The business’s 50 day moving average price is $26.19 and its two-hundred day moving average price is $27.86.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.08). On average, analysts anticipate that Forte Biosciences will post -4.27 EPS for the current year.

Key Stories Impacting Forte Biosciences

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: The all-cash acquisition offer is the primary catalyst for FBRX’s move higher, with the proposed $77 price providing a substantial premium and a potential near-term liquidity event for shareholders. Argenx to Buy Forte Biosciences for $2.2 Billion
• Neutral Sentiment: Unusually heavy options activity saw traders purchase 2,105 put contracts, compared with typical volume of about 95. The surge may reflect hedging or speculation around deal-completion risk rather than a confirmed change in Forte’s fundamentals.
• Neutral Sentiment: Forte previously carried a “Moderate Buy” average brokerage rating, but the pending cash transaction means the stock’s value will likely be driven more by the merger terms and closing probability than by standalone analyst forecasts. Forte Biosciences Given Average Rating of Moderate Buy
• Negative Sentiment: Shareholder-rights firms Halper Sadeh and Ademi announced investigations into whether Forte’s board obtained a fair price and fulfilled its fiduciary duties. These reviews could create legal or timing uncertainty, although they do not currently indicate that the transaction will be terminated. FBRX Stock Alert: Halper Sadeh Investigation

Analyst Upgrades and Downgrades

FBRX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Forte Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Forte Biosciences in a report on Wednesday, July 8th. TD Cowen cut Forte Biosciences to a “hold” rating in a research note on Monday. Finally, Barclays began coverage on shares of Forte Biosciences in a research report on Tuesday, July 21st. They issued an “overweight” rating and a $74.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.75.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.